Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rosetta Genomics, a developer of microRNA-based molecular diagnostics, has launched its first diagnostic test, miRview squamous. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia.
Subscribe to our email newsletter
According to the company, the test has a reported sensitivity of 97%, and a specificity of 91% in identifying squamous cell lung cancer. Classification accuracy was measured in a blinded test of a validation set of 64 samples, compared to the consensus diagnosis of at least two pathologists. In blinded tests of lab-to-lab concordance, two labs reached the same classification in more than 95% of classified samples.
Amir Avniel, president and CEO of Rosetta Genomics, said: “The introduction of miRview squamous, our first microRNA-based test, is a landmark event for us at Rosetta Genomics. We are excited to be offering the first objective diagnostic test for differentiation of non-small cell lung cancer (NSCLC) patients, which is based on our proprietary microRNA technology.
“miRview squamous offers physicians a standardized, quantitative diagnostic tool which may assist in determining the appropriate targeted therapy for NSCLC.”